Academic Journal
Beyond disease treatment and prevention: From geroscience and molecular hallmarks to gerotherapeutics and precision geromedicine.
| Τίτλος: | Beyond disease treatment and prevention: From geroscience and molecular hallmarks to gerotherapeutics and precision geromedicine. |
|---|---|
| Συγγραφείς: | Peng LN; Center for Geriatrics and Gerontology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.; Center for Healthy Longevity and Aging Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC., Hsiao FY; Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.; School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.; Department of Pharmacy, College of Medicine, National Taiwan University Hospital, Taipei, Taiwan, ROC., Chen LK; Center for Geriatrics and Gerontology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.; Center for Healthy Longevity and Aging Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.; Taipei Municipal Gan-Dau Hospital (Managed by Taipei Veterans General Hospital), Taipei, Taiwan, ROC. |
| Πηγή: | Journal of the Chinese Medical Association : JCMA [J Chin Med Assoc] 2026 May 01; Vol. 89 (5), pp. 323-333. Date of Electronic Publication: 2026 Apr 10. |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Wolters Kluwer Health Country of Publication: Netherlands NLM ID: 101174817 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1728-7731 (Electronic) Linking ISSN: 17264901 NLM ISO Abbreviation: J Chin Med Assoc Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2019- : [Alphen aan den Rijn, The Netherlands] : Wolters Kluwer Health Original Publication: Taipei, Taiwan : Chinese Medical Association, c2003- |
| Ιατρικοί όροι (MeSH): | Geroscience* , Geriatrics* , Precision Medicine*, Aging/physiology ; Humans ; Animals |
| Περίληψη: | Geroscience-the interdisciplinary field investigating the causal relationship between the biology of aging and age-related chronic disease-has undergone a remarkable evolution since its formalization within the United States National Institutes of Health in the early 2010s. Grounded in the recognition that aging is the paramount modifiable risk factor for most noncommunicable diseases, geroscience has produced a coherent molecular taxonomy of aging processes (12 hallmarks), delineated proaging and antiaging molecular pathways (gerogenes, gerosuppressors, and gerozymes), and catalyzed a new clinical vocabulary-geroprotection, gerodiagnostics, and gerotherapeutics. Two institutional milestones anchor the field's translational ambitions: the World Health Organization's (WHO) codification of Ageing-Associated Decline in Intrinsic Capacity as International Classification of Disease (ICD)-11 code MG2A; and the United States Food and Drug Administration's (FDA) acceptance of the Targeting Aging with Metformin (TAME) trial-the first prospective clinical trial designed to delay aging as a composite multidisease outcome, currently underway. The biomarker science of aging has advanced in parallel, from first-generation DNA methylation clocks to organ-specific plasma proteomic signatures capable of predicting various age-related diseases with clinical-grade precision. The gerotherapeutic landscape has expanded substantially. Metformin, which engages more aging hallmarks than any other candidate gerotherapeutic, provided the regulatory impetus for TAME; in a rigorous 40-month multiomics study in cynomolgus monkeys, it decelerated plasma proteomic biological age by 6.41 years-the strongest pharmacological evidence to date for systemic biological age modification in a primate model. Senolytics and senomorphics target senescent cell burden; SGLT-2 inhibitors are notable for their indirect senolytic mechanism, enhancing immunosurveillance of senescent cells glucagon-like peptide-1 (GLP-1) receptor agonists attenuate inflammaging; NAD + precursors restore mitochondrial and sirtuin function; and the gerozyme (15-hydroxyprostaglandin dehydrogenase [15-PGDH]) inhibitor offers a mechanistically distinct proregenerative approach with emerging relevance as an adjunct to GLP-1 receptor agonist therapy. Multidomain lifestyle programs address multiple aging hallmarks simultaneously and have demonstrated measurable intrinsic capacity improvement in randomized trials. Building on these foundations, this review proposes the Geroscience-Responsive Aging Care Ecosystem (GRACE)-a three-element service model operationalizing geroscience and gerotherapeutic evidence within the WHO Integrated Care for Older People (ICOPE) framework. (Copyright © 2026, the Chinese Medical Association.) |
| Competing Interests: | Conflicts of interest: Dr. Li-Ning Peng and Dr. Liang-Kung Chen, editorial board members at Journal of the Chinese Medical Association , had no role in the peer review process of or decision to publish this article. The other authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article. |
| References: | J Prev Alzheimers Dis. 2022;9(1):22-29. (PMID: 35098970) Cell. 2024 Oct 31;187(22):6358-6378.e29. (PMID: 39270656) Elife. 2022 Jan 14;11:. (PMID: 35029144) Arch Gerontol Geriatr. 2024 Jan;116:105258. (PMID: 37944200) J Gerontol A Biol Sci Med Sci. 2014 Jun;69 Suppl 1:S1-3. (PMID: 24833579) Lancet. 2019 Oct 12;394(10206):1365-1375. (PMID: 31609228) Nat Aging. 2026 Jan;6(1):162-180. (PMID: 41299092) Geroscience. 2025 Oct;47(5):6399-6409. (PMID: 40335817) Lancet Healthy Longev. 2021 Nov;2(11):e712-e723. (PMID: 36098028) Lancet Healthy Longev. 2025 Mar;6(3):100695. (PMID: 40147475) Lancet. 2019 Oct 12;394(10206):1376-1386. (PMID: 31609229) Lancet Healthy Longev. 2022 Jun;3(6):e394-e404. (PMID: 36098317) J Am Med Dir Assoc. 2024 May;25(5):757-763.e4. (PMID: 37949432) Aging Cell. 2020 Feb;19(2):e13080. (PMID: 31833194) Cell. 2013 Jun 6;153(6):1194-217. (PMID: 23746838) Arch Gerontol Geriatr. 2024 Jan;116:105162. (PMID: 37598465) J Nutr Health Aging. 2025 Sep;29(9):100637. (PMID: 40706485) NPJ Aging. 2025 May 10;11(1):35. (PMID: 40348751) Cell Metab. 2020 Jul 7;32(1):15-30. (PMID: 32333835) Cell. 2025 Apr 17;188(8):2043-2062. (PMID: 40250404) Proc Natl Acad Sci U S A. 2026 Jun 9;123(23):e2606533123. (PMID: 42228536) Nat Med. 2025 Aug;31(8):2703-2711. (PMID: 40634782) Mech Ageing Dev. 2020 Jul;189:111230. (PMID: 32251691) Aging (Albany NY). 2018 Apr 18;10(4):573-591. (PMID: 29676998) Arch Gerontol Geriatr. 2024 Feb;117:105164. (PMID: 37708578) Nat Rev Cardiol. 2018 Sep;15(9):505-522. (PMID: 30065258) Lancet. 2016 May 21;387(10033):2145-2154. (PMID: 26520231) Cell. 2023 Jan 19;186(2):243-278. (PMID: 36599349) Cell. 2014 Nov 6;159(4):709-13. (PMID: 25417146) Aging Cell. 2024 Jan;23(1):e14034. (PMID: 38038340) J Am Coll Cardiol. 2023 Aug 15;82(7):631-647. (PMID: 37389519) Sci Transl Med. 2023 Oct 11;15(717):eadg1485. (PMID: 37820010) Age Ageing. 2024 Mar 1;53(3):. (PMID: 38520141) Aging (Albany NY). 2025 Aug 7;17(8):2079-2088. (PMID: 40778880) Nat Aging. 2024 Jul;4(7):926-938. (PMID: 38816549) J Frailty Aging. 2021;10(2):103-109. (PMID: 33575698) Clin Nutr. 2022 Apr;41(4):958-989. (PMID: 35306388) J Chin Med Assoc. 2024 Nov 1;87(11):980-987. (PMID: 39257038) Science. 2026 Mar 5;391(6789):1053-1062. (PMID: 41308124) Nat Med. 2023 Jul;29(7):1623-1630. (PMID: 37464029) Cell Metab. 2024 Feb 6;36(2):354-376. (PMID: 38181790) Trends Genet. 2025 Jul;41(7):552-553. (PMID: 40533324) Lancet Healthy Longev. 2025 Jun;6(6):100725. (PMID: 40517785) Diabetes Obes Metab. 2014 Nov;16(11):1165-73. (PMID: 25041462) Science. 2021 Jan 29;371(6528):. (PMID: 33303683) Nat Aging. 2025 Nov;5(11):2164-2175. (PMID: 41188603) J Chin Med Assoc. 2024 Jan 1;87(1):3-4. (PMID: 37991370) Nat Aging. 2024 Sep;4(9):1177-1179. (PMID: 39122838) Lancet Healthy Longev. 2022 Jul;3(7):e457-e459. (PMID: 36102756) J Am Geriatr Soc. 2024 May;72(5):1605-1607. (PMID: 38650350) Nat Med. 2024 Sep;30(9):2450-2460. (PMID: 39117878) Aging (Albany NY). 2019 Jan 21;11(2):303-327. (PMID: 30669119) Cell Res. 2024 Jul;34(7):463-466. (PMID: 38802575) Geriatr Gerontol Int. 2025 May;25(5):657-662. (PMID: 40229144) Arch Gerontol Geriatr. 2026 Jan;140:106057. (PMID: 41125518) J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13731. (PMID: 39971708) Geroscience. 2017 Feb;39(1):1-5. (PMID: 28299635) Nat Aging. 2023 Dec;3(12):1474-1479. (PMID: 37985720) Circ Res. 2018 Sep 14;123(7):740-744. (PMID: 30355074) Innov Aging. 2025 Sep 25;9(Suppl 1):S24-S32. (PMID: 41458888) N Engl J Med. 2024 Aug 8;391(6):538-548. (PMID: 39115063) Genome Biol. 2013;14(10):R115. (PMID: 24138928) Arch Gerontol Geriatr. 2025 Jan;128:105596. (PMID: 39232423) Nat Biotechnol. 2025 Nov;43(11):1741-1742. (PMID: 41225210) Science. 2015 Dec 4;350(6265):1191-3. (PMID: 26785476) Cell Metab. 2016 Jun 14;23(6):1060-1065. (PMID: 27304507) Aging Cell. 2019 Dec;18(6):e13039. (PMID: 31557380) |
| Contributed Indexing: | Keywords: Biological age; Geroscience; Gerotherapeutics; Intrinsic capacity; Precision geromedicine |
| Entry Date(s): | Date Created: 20260410 Date Completed: 20260714 Latest Revision: 20260926 |
| Update Code: | 20260926 |
| PubMed Central ID: | PMC13193294 |
| DOI: | 10.1097/JCMA.0000000000001374 |
| PMID: | 41957871 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!